Combination Phentermine –Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study

Conclusion: Phentermine–topiramate could be helpful for weight loss and reduction of binge-eating symptoms in patients with obesity or overweight in addition to BED. Controlled studies are warranted. Binge-eating disorder (BED), an eating disorder recognized in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), is characterized by recurrent and distressing episodes of binge eating (eating an unusually large amount of food with a sense of loss of control over eating) without inappropriate compensatory weight-loss behaviors.1 Known as the most common eating disorder, BED is strongly associated with obesity and obesity-related medical conditions.2 Treatment targets in BED patients include decreasing binge-eating behavior and, among individuals with overweight or obesity, excessive body weight. Various treatment strategies, including psychological and pharmacological interventions, aim to reduce binge eating in patients with BED, but not all patients adequately respond to these strategies. Moreover, these treatments are generally either ineffective for weight loss or are associated with problematic adverse events.3 Lisdexamfetamine dimesylate (LDX), the only medication with regulatory approval for the treatment of BED, is not indicated for weight loss, and its efficacy for the treatment of obesity has not been established.4 Therefore, well-tolerated novel treatments that reduce both binge-eating behavior and body weight are needed for the manageme...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Drug Development Original Research binge eating obesity phentermine–topiramate Qsymia® weight loss Source Type: research